{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:47:33Z","timestamp":1791092853062,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T00:00:00Z","timestamp":1597276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40264-020-00988-3","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T16:10:19Z","timestamp":1597335019000},"page":"1287-1296","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-9265","authenticated-orcid":false,"given":"Gabrielle","family":"Kornmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,13]]},"reference":[{"issue":"2","key":"988_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.bbadis.2010.07.007","volume":"1812","author":"C Stadelmann","year":"2011","unstructured":"Stadelmann C, Wegner C, Br\u00fcck W. Inflammation, demyelination, and degeneration\u2014recent insights from MS pathology. Biochim Biophys Acta. 2011;1812(2):275\u201382.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"988_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1586\/17512433.2014.865517","volume":"7","author":"F Curtin","year":"2014","unstructured":"Curtin F, Hartung HP. Novel therapeutic options for multiple sclerosis. Expert Rev Clin Pharmacol. 2014;7(1):91\u2013104.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"17","key":"988_CR3","doi-asserted-by":"publisher","first-page":"e94387","DOI":"10.1172\/jci.insight.94387","volume":"2","author":"S Levet","year":"2017","unstructured":"Levet S, Medina J, Joanou J, Demolder A, Queruel N, R\u00e9ant K, et al. An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes. JCI Insight. 2017;2(17):e94387.","journal-title":"JCI Insight"},{"issue":"9","key":"988_CR4","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1111\/dom.13357","volume":"20","author":"F Curtin","year":"2018","unstructured":"Curtin F, Bernard C, Levet S, Perron H, Porchet H, M\u00e9dina J, et al. A new therapeutic approach for type 1 diabetes: rationale for GNbAC1, an anti-HERV-W-Env monoclonal antibody. Diabetes Obes Metab. 2018;20(9):2075\u201384.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"988_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12016-009-8170-x","volume":"39","author":"H Perron","year":"2010","unstructured":"Perron H, Lang A. The human endogenous retrovirus link between genes and environment in multiple sclerosis and in multifactorial diseases associating neuroinflammation. Clin Rev Allergy Immunol. 2010;39(1):51\u201361.","journal-title":"Clin Rev Allergy Immunol"},{"key":"988_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ebiom.2016.03.001","volume":"6","author":"R Faucard","year":"2016","unstructured":"Faucard R, Madeira A, Gehin N, Authier FJ, Panaite PA, Lesage C, et al. Human endogenous retrovirus and neuroinflammation in chronic inflammatory demyelinating polyradiculoneuropathy. EBioMedicine. 2016;6:190\u20138. https:\/\/doi.org\/10.1016\/j.ebiom.2016.03.001.","journal-title":"EBioMedicine"},{"issue":"12","key":"988_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11892-019-1256-9","volume":"19","author":"S Levet","year":"2019","unstructured":"Levet S, Charvet B, Bertin A, Deschaumes A, Perron H, Hober D. Human endogenous retroviruses and type 1 diabetes. Curr Diabetes Rep. 2019;19(12):141.","journal-title":"Curr Diabetes Rep"},{"issue":"4","key":"988_CR8","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.molmed.2018.02.007","volume":"24","author":"P Kury","year":"2018","unstructured":"Kury P, Nath A, Creange A, Dolei A, Marche P, Gold J, et al. Human endogenous retroviruses in neurological diseases. Trends Mol Med. 2018;24(4):379\u201394.","journal-title":"Trends Mol Med"},{"issue":"12","key":"988_CR9","doi-asserted-by":"publisher","first-page":"e80128","DOI":"10.1371\/journal.pone.0080128","volume":"8","author":"H Perron","year":"2013","unstructured":"Perron H, Dougier-Reynaud HL, Lomparski C, Popa I, Firouzi R, Bertrand JB, et al. Human endogenous retrovirus protein activates innate immunity and promotes experimental allergic encephalomyelitis in mice. PLoS One. 2013;8(12):e80128.","journal-title":"PLoS One"},{"key":"988_CR10","doi-asserted-by":"publisher","first-page":"7636","DOI":"10.4049\/jimmunol.176.12.7636","volume":"176","author":"A Rolland","year":"2006","unstructured":"Rolland A, Jouvin-Marche E, Viret C, Faure M, Perron H, Marche PN. The envelope protein of a human endogenous retrovirus-W family activates innate immunity through CD14\/TLR4 and promotes Th1-like responses. J Immunol. 2006;176:7636\u201344.","journal-title":"J Immunol"},{"key":"988_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4161\/19420862.2014.985021","volume":"7","author":"F Curtin","year":"2015","unstructured":"Curtin F, Perron H, Kromminga A, Porchet H, Lang AB. Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein. MAbs. 2015;7:265\u201375.","journal-title":"MAbs"},{"key":"988_CR12","doi-asserted-by":"publisher","first-page":"8728","DOI":"10.1093\/nar\/gkr562","volume":"39","author":"K Trejbalova","year":"2011","unstructured":"Trejbalova K, Blazkova J, Matouskova M, Kucerova D, Pecnova L, Vernerova Z, et al. Epigenetic regulation of transcription and splicing of syncytins, fusogenic glycoproteins of retroviral origin. Nucleic Acids Res. 2011;39:8728\u201339. https:\/\/doi.org\/10.1093\/nar\/gkr562.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"988_CR13","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.clinthera.2012.11.006","volume":"34","author":"F Curtin","year":"2012","unstructured":"Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, et al. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study. Clin Ther. 2012;34(12):2268\u201378.","journal-title":"Clin Ther"},{"issue":"5","key":"988_CR14","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1080\/19420862.2016.1168956","volume":"8","author":"F Curtin","year":"2016","unstructured":"Curtin F, Vidal V, Bernard C, Kromminga A, Lang AB, Porchet H. Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: a phase 1 study. MAbs. 2016;8(5):854\u201360. https:\/\/doi.org\/10.1080\/19420862.2016.1168956.","journal-title":"MAbs"},{"issue":"9","key":"988_CR15","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.clinthera.2019.05.020","volume":"41","author":"H Porchet","year":"2019","unstructured":"Porchet H, Vidal V, Kornmann G, Malpass S, Curtin F. A high-dose pharmacokinetic study of a new IgG4 monoclonal antibody temelimab\/GNbAC1 antagonist of an endogenous retroviral protein pHERV-W Env. Clin Ther. 2019;41(9):1737\u201346.","journal-title":"Clin Ther"},{"issue":"285","key":"988_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jneuroim.2015.05.019","volume":"15","author":"T Derfuss","year":"2015","unstructured":"Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, et al. A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients\u2014a twelve month follow-up. J Neuroimmunol. 2015;15(285):68\u201370.","journal-title":"J Neuroimmunol"},{"key":"988_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.msard.2016.07.002","volume":"9","author":"F Curtin","year":"2016","unstructured":"Curtin F, Porchet H, Glanzman R, Schneble HM, Vidal V, Audoli-Inthavong ML, et al. A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis\u2014rationale and design. Mult Scler Relat Disord. 2016;9:95\u2013100.","journal-title":"Mult Scler Relat Disord"},{"key":"988_CR18","unstructured":"Hartung HP, Selmaj K, Glanzman R, Curtin F, Porchet H, Schneble HM, et al. Week 48 results from a phase IIb trial of GNbAC1 in patients with relapsing remitting multiple sclerosis (CHANGE-MS; clinical trial assessing the HERV-W Env antagonist GNbAC1 for Efficacy in MS). ECTRIMS Congress; 10\u201312 Oct 2018, Berlin."},{"key":"988_CR19","unstructured":"Hartung HP, Cree B, Derfuss T, Sormani MP, Frederik B, Curtin F, et al. Neuroprotective effects of temelimab in relapsing-remitting MS patients extend to 96 weeks (P1379). ECTRIMS Congress; 11\u201313 Sep 2019, Stockholm."},{"key":"988_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14010","author":"F Curtin","year":"2020","unstructured":"Curtin F, Champion B, Davoren P, Duke S, Ekinci EI, Gilfillan C, et al. A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes. Diabetes Obes Metab. 2020. https:\/\/doi.org\/10.1111\/dom.14010.","journal-title":"Diabetes Obes Metab"},{"key":"988_CR21","unstructured":"International conference on harmonisation (ICH) Guideline For Good Clinical Practice: Consolidated Guidance (R2-integrated addendum). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf."},{"key":"988_CR22","unstructured":"International conference on harmonisation (ICH) E2A: clinical safety data management: definitions and standards for expedited reporting. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/international-conference-harmonisation-technical-requirements-registration-pharmaceuticals-human-use_en-15.pdf."},{"key":"988_CR23","unstructured":"\u2018CT-3\u2019: Communication from the Commission (Note: European Commission)\u2014detailed guidance on the collection, verification and presentation of adverse event\/reaction reports arising from clinical trials on medicinal products for human use (2011\/C 172). https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:C:2011:172:0001:0013:EN:PDF."},{"key":"988_CR24","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1212\/NXI.0000000000000018","volume":"1","author":"JQ Tran","year":"2014","unstructured":"Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjeset MO, et al. Randomized phase I trials of the safety\/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. Neurol Neuroimmunol Neuroinflamm. 2014;1:e18.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"988_CR25","doi-asserted-by":"publisher","first-page":"1206e1214","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"J Jankovic","year":"2018","unstructured":"Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-a-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol. 2018;75:1206e1214.","journal-title":"JAMA Neurol"},{"issue":"8","key":"988_CR26","doi-asserted-by":"publisher","first-page":"e00279\u201317","DOI":"10.1128\/AAC.00279-17","volume":"61","author":"JL Jeremy","year":"2017","unstructured":"Jeremy JL, Derby MA, Zhang Y, Deng R, Larouche R, Anderson M, et al. A phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of an anti-influenza B virus monoclonal antibody, MHAB5553A, in healthy volunteers. Antimicrob Agents Chemother. 2017;61(8):e00279\u201317. https:\/\/doi.org\/10.1128\/AAC.00279-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"988_CR27","doi-asserted-by":"crossref","first-page":"746769","DOI":"10.1155\/2014\/746769","volume":"2014","author":"D Nadler","year":"2014","unstructured":"Nadler D, Zurbenko I. Estimating cancer latency times using a Weibull model. Adv Epidemiol. 2014;2014:746769.","journal-title":"Adv Epidemiol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00988-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-020-00988-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-020-00988-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:38:50Z","timestamp":1628815130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-020-00988-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,13]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["988"],"URL":"https:\/\/doi.org\/10.1007\/s40264-020-00988-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,13]]},"assertion":[{"value":"13 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical trials described in this article were supported by GeNeuro SA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gabrielle Kornmann and Fran\u00e7ois Curtin are employees of GeNeuro SA and may own company stock\/stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All studies reviewed in this paper were approved by local Ethics Committees and National Health Authorities and complied with international and national laws.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For all studies reviewed in this paper, freely given informed consent to participate in the study was obtained from participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"For all studies reviewed in this paper, participants consented to have the study results published in a medical journal.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during the current analysis are not publicly available because access to pharmacovigilance data must always be considered in respect to European Union laws, which protect the patients\u2019 rights to personal privacy; however, upon reasonable request, the data may be made available by contacting the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"GK conceived and designed the analysis and wrote the paper. FC conceived and designed the analysis and reviewed the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}